However, the few clinical trials in prostate cancer using drugs targeting Epidermal Growth Factor Receptor (EGFR) [40,41], VEGFR-2 [42] and HER2 [43,44,45] were discouraging so far. This evidence concerns the gene KDR and Familial prostate cancer.